help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gamallo, C.
Right arrow Articles by Armas, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gamallo, C.
Right arrow Articles by Armas, A.
(American Journal of Pathology. 1999;155:527-536.)
© 1999 American Society for Investigative Pathology

Regular Articles

ß-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas

Relationship with ß-Catenin Gene Mutations,Clinicopathological Features, and Clinical Outcome

Carlos Gamallo*, José Palacios*, Gema Moreno*, Jorge Calvo de Mora*, Asunción Suárez* and Alvaro Armas{dagger}

From Departamento de Anatomía Patológica*
and Departamento de Ginecología y Obstetricia,{dagger}
Hospital La Paz, Madrid, Spain

The immunohistochemical expression pattern of ß-catenin has been correlated with ß-catenin gene mutations, clinicopathological features, and disease outcome in 69 stage I and II ovarian carcinomas. ß-Catenin expression was localized in the nuclei, in addition to the cytoplasm and membrane, in 11 tumors (16%): nine endometrioid carcinomas with widespread nuclear expression and two serous carcinomas with focal nuclear expression. The remaining 58 carcinomas (84%) only had membranous ß-catenin expression. All but one of the endometrioid carcinomas with nuclear ß-catenin expression had considerable squamous metaplasia, and five of these cases had large areas of endometrioid tumor of low malignant potential. In addition, ß-catenin nuclear expression was observed in atypical epithelial cells in endometriotic glands adjacent to an endometrioid carcinoma. Sequencing was performed on 25 tumors and corresponding normal tissue: all 13 endometrioid tumors as well as 12 carcinomas of other histological types (four serous, two clear cell, two mucinous, and two mixed). There were oncogenic mutations in the phosphorylation sequence for GSK-3ß in exon 3 of the ß-catenin gene in seven endometrioid carcinomas with ß-catenin nuclear expression. Three mutations affected codon 32 (D32G, D32Y, and D32Y), one affected codon 33 (S33C), two affected codon 37 (S37C and S37F), and one affected codon 41 (T41A). No mutations were observed in the other 18 carcinomas analyzed, comprising two endometrioid and two serous carcinomas with ß-catenin nuclear expression, and 14 carcinomas of different histological types with only membranous expression. In the univariate and multivariate survival analyses, ß-catenin nuclear expression was selected as an indicator of good prognosis, because no patient whose tumor expressed ß-catenin in the nuclei showed relapses or died, in contrast to the 19 relapses and deaths among patients with tumors that only had ß-catenin membranous expression, including three of the four patients with endometrioid carcinomas. Oncogenic ß-catenin mutation is characteristic of a group of endometrioid carcinomas with a good prognosis, most of which originate from previous benign or borderline lesions. Endometrioid carcinomas with exclusively membranous expression of ß-catenin seem to represent a different subgroup of carcinomas that probably have a worse prognosis. In early-stage ovarian cancer, determination of the ß-catenin expression pattern could prove to be a useful marker for selecting low-risk patients.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. Saegusa, M. Hashimura, T. Kuwata, M. Hamano, Y. Wani, and I. Okayasu
A functional role of Cdx2 in {beta}-catenin signaling during transdifferentiation in endometrial carcinomas
Carcinogenesis, September 1, 2007; 28(9): 1885 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Gumireddy, F. Sun, A. J. Klein-Szanto, J. M. Gibbins, P. A. Gimotty, A. J. Saunders, P. G. Schultz, and Q. Huang
In vivo selection for metastasis promoting genes in the mouse
PNAS, April 17, 2007; 104(16): 6696 - 6701.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
C. Furuse, P. R. Cury, A. Altemani, D. dos Santos Pinto Junior, N. S. de Araujo, and V. C. de Araujo
{beta}-Catenin and E-Cadherin Expression in Salivary Gland Tumors.
International Journal of Surgical Pathology, July 1, 2006; 14(3): 212 - 217.
[Abstract] [PDF]

Home page
 J. Clin. Pathol.Home page
K A Voutilainen, M A Anttila, S M Sillanpaa, K M Ropponen, S V Saarikoski, M T Juhola, and V-M Kosma
Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer
J. Clin. Pathol., May 1, 2006; 59(5): 460 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Pollheimer, T. Loregger, S. Sonderegger, L. Saleh, S. Bauer, M. Bilban, K. Czerwenka, P. Husslein, and M. Knofler
Activation of the Canonical Wingless/T-Cell Factor Signaling Pathway Promotes Invasive Differentiation of Human Trophoblast
Am. J. Pathol., April 1, 2006; 168(4): 1134 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. M. Bachmann, O. Straume, H. E. Puntervoll, M. B. Kalvenes, and L. A. Akslen
Importance of P-Cadherin, {beta}-Catenin, and Wnt5a/Frizzled for Progression of Melanocytic Tumors and Prognosis in Cutaneous Melanoma
Clin. Cancer Res., December 15, 2005; 11(24): 8606 - 8614.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Shedden, M. P. Kshirsagar, D. R. Schwartz, R. Wu, H. Yu, D. E. Misek, S. Hanash, H. Katabuchi, L. H. Ellenson, E. R. Fearon, et al.
Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas
Clin. Cancer Res., March 15, 2005; 11(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Provost, Y. Yamamoto, I. Lizardi, J. Stern, T. G. D'Aquila, R. B. Gaynor, and D. L. Rimm
Functional Correlates of Mutations in {beta}-Catenin Exon 3 Phosphorylation Sites
J. Biol. Chem., August 22, 2003; 278(34): 31781 - 31789.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. M. Maelandsmo, R. Holm, J. M. Nesland, O. Fodstad, and V. A. Florenes
Reduced {beta}-Catenin Expression in the Cytoplasm of Advanced-Stage Superficial Spreading Malignant Melanoma
Clin. Cancer Res., August 1, 2003; 9(9): 3383 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Schwartz, R. Wu, S. L. R. Kardia, A. M. Levin, C.-C. Huang, K. A. Shedden, R. Kuick, D. E. Misek, S. M. Hanash, J. M. G. Taylor, et al.
Novel Candidate Targets of {beta}-Catenin/T-cell Factor Signaling Identified by Gene Expression Profiling of Ovarian Endometrioid Adenocarcinomas
Cancer Res., June 1, 2003; 63(11): 2913 - 2922.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
E. Karbova, B. Davidson, K. Metodiev, C. G. Trope, and J. M. Nesland
Adenomatous Polyposis Coli (APC) Protein Expression in Primary and Metastatic Serous Ovarian Carcinoma
International Journal of Surgical Pathology, July 1, 2002; 10(3): 175 - 180.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
J. Y. Leung, F. T. Kolligs, R. Wu, Y. Zhai, R. Kuick, S. Hanash, K. R. Cho, and E. R. Fearon
Activation of AXIN2 Expression by beta -Catenin-T Cell Factor. A FEEDBACK REPRESSOR PATHWAY REGULATING Wnt SIGNALING
J. Biol. Chem., June 7, 2002; 277(24): 21657 - 21665.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. E. Pawlowski, J. R. Ertel, M. P. Allen, M. Xu, C. Butler, E. M. Wilson, and M. E. Wierman
Liganded Androgen Receptor Interaction with beta -Catenin. NUCLEAR CO-LOCALIZATION AND MODULATION OF TRANSCRIPTIONAL ACTIVITY IN NEURONAL CELLS
J. Biol. Chem., May 31, 2002; 277(23): 20702 - 20710.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Zhai, R. Wu, D. R. Schwartz, D. Darrah, H. Reed, F. T. Kolligs, M. T. Nieman, E. R. Fearon, and K. R. Cho
Role of {beta}-Catenin/T-Cell Factor-Regulated Genes in Ovarian Endometrioid Adenocarcinomas
Am. J. Pathol., April 1, 2002; 160(4): 1229 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Wu, Y. Zhai, E. R. Fearon, and K. R. Cho
Diverse Mechanisms of {beta}-Catenin Deregulation in Ovarian Endometrioid Adenocarcinomas
Cancer Res., November 1, 2001; 61(22): 8247 - 8255.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev
Down-Regulation of {beta}-Catenin by Activated p53
Mol. Cell. Biol., October 15, 2001; 21(20): 6768 - 6781.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson
Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade
Cancer Res., March 1, 2001; 61(5): 2085 - 2091.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
K. Wiechen, C. Sers, A. Agoulnik, K. Arlt, M. Dietel, P. M. Schlag, and U. Schneider
Down-Regulation of Caveolin-1, a Candidate Tumor Suppressor Gene, in Sarcomas
Am. J. Pathol., March 1, 2001; 158(3): 833 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
P. Polakis
Wnt signaling and cancer
Genes & Dev., August 1, 2000; 14(15): 1837 - 1851.
[Full Text]

Home page
 Genes Dev.Home page
F. T. Kolligs, B. Kolligs, K. M. Hajra, G. Hu, M. Tani, K. R. Cho, and E. R. Fearon
gamma -Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta -catenin
Genes & Dev., June 1, 2000; 14(11): 1319 - 1331.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society for Investigative Pathology.